Biomerica Inc (BMRA) Q3 2026 Earnings Call Transcript

Why It Matters

The results demonstrate Kestra’s ability to capture market share in a rapidly expanding wearable defibrillator market while improving profitability and payer coverage, positioning it for sustained long‑term growth.

Key Takeaways

• Revenue up 63% YoY to $24.6M
• Gross margin reached 52.6%, nine quarters expanding
• Assure prescriptions exceed 5,400, conversion 46%
• Florida Medicaid and VA contracts broaden payer network
• BioBeat partnership adds cuffless blood‑pressure monitoring

Pulse Analysis

The wearable cardioverter defibrillator (WCD) market remains in its early growth phase, with industry analysts estimating low‑ to mid‑teens percent expansion in 2025. Despite strong clinical evidence, adoption is still limited, leaving a sizable unmet need. Kestra’s Assure system, bolstered by its recent FDA‑approved algorithm that cuts false alarms and inappropriate shocks, directly addresses clinician concerns, helping to unlock this latent demand and accelerate market penetration.

Financially, Kestra delivered a standout quarter: revenue surged 63% while gross margin climbed to 52.6%, reflecting both higher in‑network billing mix and economies of scale in its rental model. Operating leverage is improving as the company scales its sales force to 130 territories and invests in revenue‑cycle automation, offsetting higher GAAP expenses. The raised FY2026 revenue outlook to $93 million underscores confidence that the momentum will translate into multi‑digit top‑line growth and a path toward profitability.

Strategically, Kestra is widening its payer footprint by securing managed Medicaid status in Florida and inclusion on the Veterans Affairs Federal Supply Schedule, which lifts the in‑network billing mix into the low‑80% range. The $5 million equity stake in BioBeat’s MyoV platform adds ambulatory blood‑pressure monitoring, a differentiator that aligns with the high hypertension prevalence among WCD patients. Together, these initiatives deepen clinical value, improve reimbursement capture, and set the stage for Kestra to become a dominant player as the WCD market matures.